Pathogenetic features of anemia of chronic diseases in patients with malignant neoplasms and rheumatic pathology

Objective: to study the importance of cytokines, hepcidin, a soluble transferrin receptor, iron metabolism in the development of anemia of chronic diseases in patients with malignant neoplasms and rheumatic pathology, to identify the leading factors in the development of anemia for each of the studied groups and to develop a working classification of anemia of chronic diseases.

Materials and methods. 63 patients with rheumatic pathology were examined. The study group included 41 (17 men/24 women, average age 53.4 ± 4 years) patients with anemia, the control group included 22 (9 men/13 women, age 49.3 ± 1.78 years) patients without anemia. The patients (n = 63) with stage II–IV malignant neoplasms were examined. The study group included 41 patients with anemia (34 men/7 women, age 67.1 ± 9.9 years), in the control group 22 patients without it (17 men/5 women, age 60.2 ± 14.9 years). The number of red blood cells, the hemoglobin level, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, concentrations of serum iron, total iron binding capacity (TIBC), ferritin, transferrin, C-reactive protein (CRP), transferrin saturation index (TSI), and soluble transferrin receptor (sTfR), hepcidin, interleukin (IL) – 6, – 10, tumor necrosis factor-α (TNF-α) were determined. Mann – Whitney U Test was applied to check for statistically significant differences in study samples.

Results. Compared with the control group, elevated concentrations of ferritin, CRP, hepcidin, sTfR and IL-6 (p <0.05) were found for patients with rheumatic pathology and anemia and no differences were found in the concentrations of iron, TIBC, TSI, transferrin. For patients with solid malignant neoplasms and anemia, lower concentrations of iron, TIBC, TSI and higher concentrations of CRP, hepcidin, sTfR, IL-6, IL-10, TNF-α (p <0.05) are shown in comparison with the control group and there were no differences in the concentrations of ferritin, transferrin (p >0.05).

Conclusion. The multicomponent anemia genesis in patients with cancer and rheumatic pathology is shown. The contribution of each mechanism to the development of anemia may vary depending on the specific nosological form. In patients with cancer, functional iron deficiency, activation of IL-6, IL-10, TNF-α synthesis and an increase in hepcidin synthesis lead to the development of anemia of chronic diseases. In patients with a rheumatic profile and anemia, a more pronounced synthesis of hepcidin and an increase IL-6 concentration are indicated. A working version of the classification of anemia of chronic diseases based on the leading pathogenetic factor is proposed (with a predominant iron deficiency, with impaired regulatory mechanisms of erythropoiesis, with insufficient production of erythropoietin).

1. Weiss G., Goodnough L. Anemia of chronic disease. New Eng J Med 2005;352:1011–23. DOI: 10.1056/NEJMra041809.

2. Stuklov N.I., Kozinets G.I., Tyurina N.G. Hematology Tutorial. Moscow: Prakticheskaya meditsina, 2018. P. 336. (In Russ).

3. Poggiali E., Migone De Amicis M., Motta I. Anemia of chronic disease: a unique defect of iron recycling for many different chronic diseases. Eur J Intern Med 2014;25(1):12–7. DOI: 10.1016/j.ejim.2013.07.011.

4. Ludwig H., Van B.S., Barrett-Lee P. et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293–306. DOI: 10.1016/j.ejca.2004.06.019.

5. Peeters H.R., Jongen-Lavrencic M., Raja A.N. et al. Course and characteristics of anaemia in patients with rheumatoid arthritis of recent onset. Ann Rheum Dis 1996;55:162–8. DOI: 10.1136/ard.55.3.162.

6. Steinmetz T., Totzke U., Schweigert M. et al. A prospective observational study of anaemia management in cancer patients – results from the German Cancer Anaemia Registry. Eur J Cancer Care 2011;20(4):493–502. DOI: 10.1111/j.1365-2354.2010.01230.x.

7. Wilson A., Yu H.T., Goodnough L.T., Nissenson A.R. Prevalence and outcome of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med 2004;116(Suppl. 7A):50S–7S. DOI: 10.1016/j.amjmed.2003.12.012.

8. Young A., Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007;21:907–27. DOI: 10.1016/j.berh.2007.05.007.

9. Papadaki H.A., Kritikos H.D., Valatas V. et al. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factoralpha antibody therapy. Blood 2002;100:474–82. DOI: 10.1182/blood-2002-01-0136.

10. Sakhin V. T., Madzhanova E.R., Kryukov E.V. et al. Anemia of chronic disease: features of pathogenesis and possible therapeutic correction(literature review and results of own research). Onkogematologiya = Oncohematology 2018;13(1):45–53. (In Russ.). DOI: 10.17650/1818-83462018-13-1-45-53.

11. Raj D.S. Role of interleukin-6 in the anemia of chronic disease. Semin Arthritis Rheum 2009;38(5):382–8. DOI: 10.1016/j.semarthrit.2008.01.006.

12. Sakhin V.T., Madzhanova E.R., Kryukov E.V. et al. Anemia of chronic disease: key mechanisms of pathogenesis in patients with malignancies and feasible classification approaches. Klinicheskaya onkogematologiya = Clinical Oncohematology 2019;12(3): 344–9. (In Russ.). DOI: 10.21320/25002139-2019-12-3-344-349.

13. Chan F.K., Cryer B., Goldstein J.L. et al. A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol 2010;37:167–74. DOI: 10.3899/jrheum.090168.

14. Grotto H.Z. Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Med Oncol 2008;25:12–21. DOI: 10.1007/s12032-007-9000-8.

15. Hematology: national guidelines. Ed.: O.A. Rukavitsin. Moscow: GEOTARMedia, 2015. Pp. 143–149.(In Russ).

16. Van Santen S., Van Dongen-Lases E.C., de Vegt F. et al. Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum 2011;63:3672–80. DOI: 10.1002/art.30623.

17. Ganz T., Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012;1823(9):1434–43. DOI: 10.1016/j.bbamcr.2012.01.014.

18. Sakhin V.T., Kryukov E.V., Rukavitsyn O.A. et al. The importance of iron metabolism, hepcidin and soluble transferrin receptor in the pathogenesis of anemia in patients with malignant neoplasms. Vestnik rossiiskoy voenno-medicinskoy academii = Bulletin of the Russian Military Medical Academy 2018;63(3):91–4. (In Russ.).

19. Siebert S., Williams B.D., Henley R. et al. Single value of serum transferrin receptor is not diagnostic for the absence of iron stores in anaemic patients with rheumatoid arthritis. Clin Lab Haematol 2002;25:155–60. DOI: 10.1046/j.1365-2257.2003.00509.x.

20. Atkinson S.H., Rockett K.A., Morgan G. et al. Tumor necrosis factor SNP haplotypes are associated with iron deficiency anemia in West African children. Blood 2008;112(10):4276–83. DOI: 10.1182/blood-2008-06-162008.

21. Nairz M., Theurl I., Swirski F.K. et al. “Pumping iron” – how macrophages handle iron at the systemic, microenvironmental, and cellular levels. Pflugers Arch 2017;469(3–4):397–418. DOI: 10.1007/s00424-017-1944-8.

22. Miyanishi M., Tada K., Koike M. et al. Identification of Tim4 as a phosphatidylserine receptor. Nature 2007;450(7168): 435–9. DOI: 10.1038/nature06307.

23. Nemeth E., Rivera S., Gabayan V. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271–8. DOI: 10.1172/JCI20945.

24. De Lurdes Agostinho Cabrita A., Pinho A., Malho A. et al. Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5. Intl Urol Nephrol 2011;43:835–40. DOI: 10.1007/s11255-010-9805-9.